Cassava Sciences Inc (SAVA)

[tootalljones]

The BIOGEN drug has been variously estimated to be worth 20 to 35 billion to that company, which of course can deliver the drug, but has a depleting pipeline, so a ton of the market cap is in their new crooked drug. Drug delivery in this day and age, where sales can take place over the internet, where drug reps are going the way of the dinosaur, cannnot be worth all that much.....who knows, a couple billion at most /but who knows..

This does not include ROW, rest of world sales, nor does it include the many other things that SAVA's drug might be used as a therapy for, the list of CNS maladies is endless.

Nor does it take into account the massive OFF LABEL markets. I have heard various statistics, but they are that either 1 in 4 or 1 in 5 prescriptions in america today are off label.

The moment it is approved, this thing is gonna be used for everything, and this is why BIIB should pay 8 billion today and grab SAVA for 200 bucks a share. Each milestone the drug achieves makes it more valuable and it will run BIIB drug off the market in a couple months, as soon as people hear, they will switch. That day.